Who makes Nephrotrans?

Nephrotrans is developed by University of Zurich.

What development phase is Nephrotrans in?

Nephrotrans is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Nephrotrans

University of Zurich · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Nephrotrans
Sponsor	University of Zurich
Modality	Small molecule
Therapeutic area	Nephrology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients (PHASE2)
Preserve-Transplant Study (PHASE4)
PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nephrotrans CI brief — competitive landscape report
Nephrotrans updates RSS · CI watch RSS
University of Zurich portfolio CI